Effect of Semaglutide on Physical Function, Body Composition, and Biomarkers of Aging in Older Adults With Overweight and Insulin Resistance: Protocol for an Open-Labeled Randomized Controlled Trial
Wirkung von Semaglutid auf körperliche Funktion, Körperzusammensetzung und Biomarker des Alterns bei älteren Erwachsenen mit Übergewicht und Insulinresistenz: Protokoll einer offenen randomisierten kontrollierten Studie
JMIR Research Protocols · 2024-09-13 · 13 · e62667
DOI: 10.2196/62667 ↗Auf einen Blick
Geplant ist eine randomisierte Studie bei 20 älteren Erwachsenen mit Übergewicht und Prädiabetes oder gut kontrolliertem T2DM. Verglichen werden Semaglutid plus Lifestyle-Beratung und Lifestyle-Beratung allein.
Fragestellung
Welche Effekte hat Semaglutid zusätzlich zur Lifestyle-Beratung auf Körperzusammensetzung, körperliche Funktion und Biomarker des Alterns bei älteren Erwachsenen?
Methode
Offene randomisierte kontrollierte Studie; 20 Erwachsene ab 65 Jahren mit BMI 27-40 kg/m2 und Prädiabetes oder T2DM; Randomisierung 1:1; Follow-up 5 Monate.
Ergebnisse
Primäre Endpunkte sind Veränderungen von Lean Mass, körperlicher Funktion und Biomarkern des Alterns. Semaglutid wird in der Interventionsgruppe auf 1 mg wöchentlich titriert, wenn verträglich.
Einschränkungen
Es handelt sich um ein Protokoll; Ergebnisse liegen noch nicht vor.
Schlussfolgerung der Autor:innen
Die Studie soll Wissenslücken zu klinisch bedeutsamen, nicht-glykämischen Effekten von Semaglutid bei älteren Erwachsenen schließen.
Kernaussagen
- 20 Erwachsene ab 65 Jahren werden eingeschlossen
- Vergleich: Semaglutid plus Lifestyle-Beratung vs. Lifestyle-Beratung allein
- Primäre Endpunkte: Lean Mass, körperliche Funktion, Biomarker des Alterns
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
At a glance
Randomisierte kontrollierte Studie in JMIR Research Protocols, published online on 2024-09-13. Written by Tiffany M Cortes and 9 co-authors. Institution: Division of Endocrinology, Department of Medicine, University of Texas Health Science Center San Antonio, San Antonio, TX, United States. Major MEDLINE topics: Biomarkers, Body Composition, Diabetes Mellitus, Type 2, Glucagon-Like Peptides. Cited 15 times so far (Crossref); 46 references. The full text is freely available in PubMed Central. Funded by: NIA NIH HHS.
Topics: Gerontologische Pflege
Abstract (original language)
Background
Older adults with type 2 diabetes mellitus (T2DM) or prediabetes are at increased risk of adverse changes in body composition, physical function, and aging-related biomarkers compared to those with normal glucose tolerance. Semaglutide is a glucagon-like peptide 1 receptor agonist that has been approved for T2DM and chronic weight management. Although semaglutide is effective for weight loss and T2DM management, its effects on lean body mass, physical function, and biomarkers of aging are understudied in older adults.
Objective
This study aims to compare the effects of lifestyle counseling with and that without semaglutide on body composition, physical function, and biomarkers of aging in older adults.
Methods
This is an open-label randomized controlled trial. A total of 20 adults (aged 65 years and older) with elevated BMI (27-40 kg/m2) and prediabetes or well-controlled T2DM (hemoglobin A1c 5.7%-7.5%) are recruited, stratified by sex, and randomized 1:1 to one of 2 groups (semaglutide plus lifestyle counseling vs lifestyle counseling alone) and followed up for 5 months. Those in the semaglutide group are titrated to 1 mg weekly, as tolerated, for 12 weeks. Lifestyle counseling is given by registered dietitians and based on the Diabetes Prevention Program Lifestyle Change Program. Our primary outcomes include changes in lean mass, physical function, and biomarkers of aging. Body composition is measured by dual-energy x-ray absorptiometry and includes total fat mass and lean mass. Physical function is measured by 6-minute walk distance, grip strength, and short physical performance battery. Biomarkers of aging are measured in blood, skeletal muscle, and abdominal adipose tissue to include C-reactive protein, interleukin-6, tumor necrosis factors α, and β galactosidase staining.
Results
The study was funded in December 2021 with a projected data collection period from spring 2023 through summer 2024.
Conclusions
Despite the elevated risk of adverse changes in body composition, physical function, and biomarkers of aging among older adults with glucose intolerance and elevated adiposity, the benefits and risks of commonly prescribed antihyperglycemic or weight loss medications such as semaglutide are understudied. This study aims to fill this knowledge gap to inform clinicians about the potential for additional clinically meaningful, nonglycemic effects of semaglutide. Trial Registration ClinicalTrials.gov NCT05786521; https://clinicaltrials.gov/study/NCT05786521 International Registered Report Identifier (IRRID) DERR1-10.2196/62667
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Division of Endocrinology, Department of Medicine, University of Texas Health Science Center San Antonio, San Antonio, TX, United States.
- Sam & Ann Barshop Institute for Longevity & Aging Studies, University of Texas Health Science Center San Antonio, San Antonio, TX, United States.
- San Antonio Geriatric Research, Education, and Clinical Center, South Texas Veterans Health Care System, San Antonio, TX, United States.
- Texas Diabetes Institute, University Health System, San Antonio, TX, United States.
- Division of Geriatrics, Gerontology & Palliative Medicine, Department of Medicine, University of Texas Health Science San Antonio, San Antonio, TX, United States.
- Department of Nutrition and Food Science, Texas Woman's University, Denton, TX, United States.
ORCID profiles: Tiffany M Cortes, Libia Vasquez, Monica C Serra, Ronna Robbins, Allison Stepanenko, Kevin Brown, Hannah Barrus, Annalisa Campos, Sara E Espinoza, Nicolas Musi
Funding
- NIA NIH HHS
Cite
APA
Cortes, T. M., Vasquez, L., Serra, M. C., Robbins, R., Stepanenko, A., Brown, K., Barrus, H., Campos, A., Espinoza, S. E., & Musi, N. (2024). Effect of Semaglutide on Physical Function, Body Composition, and Biomarkers of Aging in Older Adults With Overweight and Insulin Resistance: Protocol for an Open-Labeled Randomized Controlled Trial. JMIR Research Protocols, 13, e62667. https://doi.org/10.2196/62667
Vancouver
Cortes TM, Vasquez L, Serra MC, Robbins R, Stepanenko A, Brown K, et al. Effect of Semaglutide on Physical Function, Body Composition, and Biomarkers of Aging in Older Adults With Overweight and Insulin Resistance: Protocol for an Open-Labeled Randomized Controlled Trial. JMIR Research Protocols. 2024;13:e62667. doi:10.2196/62667
BibTeX
@article{Cortes2024,
author = {Cortes, Tiffany M and Vasquez, Libia and Serra, Monica C and Robbins, Ronna and Stepanenko, Allison and Brown, Kevin and Barrus, Hannah and Campos, Annalisa and Espinoza, Sara E and Musi, Nicolas},
title = {Effect of Semaglutide on Physical Function, Body Composition, and Biomarkers of Aging in Older Adults With Overweight and Insulin Resistance: Protocol for an Open-Labeled Randomized Controlled Trial},
journal = {JMIR Research Protocols},
year = {2024},
volume = {13},
pages = {e62667},
doi = {10.2196/62667}
}
EUVIMED